Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567297 | 1.00 | CA14 (0.44) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL10135563 | 0.94 | CA14 (0.46) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL10135562 | 0.94 | CA14 (0.46) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL25969976 | 0.88 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL15311554 | 0.88 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL15311557 | 0.88 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL16428936 | 0.87 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL567758 | 0.86 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL567791 | 0.86 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL27854122 | 0.86 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010146881-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | 株式会社デ・ウエスタン・セラピテクス研究所 (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | ROCK1, CIT, ROCK2 | CA14 4274/4885HDAC6 829/4885HDAC1 1843/4885 |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | CA14 3443/4885HDAC6 1027/4885HDAC1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.